KR20150056540A - 백신으로서의 클로스트리듐 디피실 폴리펩티드 - Google Patents

백신으로서의 클로스트리듐 디피실 폴리펩티드 Download PDF

Info

Publication number
KR20150056540A
KR20150056540A KR1020157005022A KR20157005022A KR20150056540A KR 20150056540 A KR20150056540 A KR 20150056540A KR 1020157005022 A KR1020157005022 A KR 1020157005022A KR 20157005022 A KR20157005022 A KR 20157005022A KR 20150056540 A KR20150056540 A KR 20150056540A
Authority
KR
South Korea
Prior art keywords
seq
ile
asn
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157005022A
Other languages
English (en)
Korean (ko)
Inventor
쎄시라 갈레오티
로산나 로이찌
마리아그라지아 피짜
마리아 스카르셀리
메에라 운니크리시난
마뉴엘 마르티넬리
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201216749A external-priority patent/GB201216749D0/en
Priority claimed from GB201216748A external-priority patent/GB201216748D0/en
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150056540A publication Critical patent/KR20150056540A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157005022A 2012-09-19 2013-09-19 백신으로서의 클로스트리듐 디피실 폴리펩티드 Withdrawn KR20150056540A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1216748.2 2012-09-19
GB201216749A GB201216749D0 (en) 2012-09-19 2012-09-19 Antigen combinations
GB1216749.0 2012-09-19
GB201216748A GB201216748D0 (en) 2012-09-19 2012-09-19 Methods of treatment
PCT/IB2013/058673 WO2014045226A1 (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Publications (1)

Publication Number Publication Date
KR20150056540A true KR20150056540A (ko) 2015-05-26

Family

ID=49725168

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157005022A Withdrawn KR20150056540A (ko) 2012-09-19 2013-09-19 백신으로서의 클로스트리듐 디피실 폴리펩티드

Country Status (13)

Country Link
US (1) US9932374B2 (enExample)
EP (1) EP2897637A1 (enExample)
JP (1) JP2015529677A (enExample)
KR (1) KR20150056540A (enExample)
CN (1) CN104582722A (enExample)
AU (1) AU2013319821A1 (enExample)
BR (1) BR112015004629A2 (enExample)
CA (1) CA2882620A1 (enExample)
IL (1) IL237172A0 (enExample)
MX (1) MX2015002485A (enExample)
RU (1) RU2015106916A (enExample)
SG (1) SG11201500980WA (enExample)
WO (1) WO2014045226A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619871B (zh) 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
US10533036B2 (en) 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
BR112020024514A2 (pt) 2018-06-19 2021-03-02 Glaxosmithkline Biologicals S.A. composição imunogênica
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059053A1 (en) * 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
WO2001070955A2 (en) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
EP1292686A1 (en) 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7226597B2 (en) * 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
EP2167119B1 (en) * 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
JP2011512817A (ja) * 2008-02-28 2011-04-28 スリーエム イノベイティブ プロパティズ カンパニー クロストリジウム・ディフィシル胞子に対する抗体及びその使用
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
JP2013512916A (ja) 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン
KR20140101835A (ko) * 2011-12-08 2014-08-20 노파르티스 아게 클로스트리듐 디피실레 톡신-기반 백신

Also Published As

Publication number Publication date
IL237172A0 (en) 2015-04-30
RU2015106916A (ru) 2016-11-10
AU2013319821A1 (en) 2015-02-26
MX2015002485A (es) 2015-06-05
WO2014045226A1 (en) 2014-03-27
US20150315248A1 (en) 2015-11-05
CN104582722A (zh) 2015-04-29
US9932374B2 (en) 2018-04-03
CA2882620A1 (en) 2014-03-27
BR112015004629A2 (pt) 2017-11-21
SG11201500980WA (en) 2015-04-29
EP2897637A1 (en) 2015-07-29
JP2015529677A (ja) 2015-10-08

Similar Documents

Publication Publication Date Title
AU2021201338B2 (en) Complete genome sequence of the methanogen methanobrevibacter ruminantium
DK3209381T3 (en) COMPOSITIONS COMPREHENSIVE BAKERY STUES
AU2016219667B2 (en) Antibacterial phage, phage peptides and methods of use thereof
KR100886095B1 (ko) 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
RU2754446C2 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
CN114555793B (zh) 基于基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发
KR20150056540A (ko) 백신으로서의 클로스트리듐 디피실 폴리펩티드
AU2016357553A1 (en) Compositions comprising bacterial strains
KR20140117433A (ko) 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신
JPH09322781A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓポリヌクレオチドおよび配列
KR101986442B1 (ko) 류머티스성 관절염용 바이오마커 및 이의 용도
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
AU2025203392A1 (en) Therapeutic bacteriophage compositions
CN112243377A (zh) 用于治疗和预防细菌相关的癌症的噬菌体
KR102224897B1 (ko) 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
KR20240021274A (ko) 반코마이신 내성 장구균에 대한 박테리오파지
KR20140120946A (ko) 브라키스피라 하이오디센테리애의 유전자와 단백질 및 이의 용도
AU2018256922B2 (en) Targeted gene disruption methods and immunogenic compositions
AU2021240230B2 (en) Vaccines and vaccine components for inhibition of microbial cells
AU777190B2 (en) Streptococcus pneumoniae polynucleotides and sequences
KR102776165B1 (ko) 병원성 대장균 또는 시겔라 속 균의 특이적 제어를 위해 축산 농가로부터 분리한 신규 박테리오파지
KR101992013B1 (ko) 병원성 장내세균에 대해 사멸능을 갖는 신규 박테리오파지 및 이의 용도
RU2773880C1 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
KR20260018598A (ko) 신규한 박테리오파지 pbec124 및 엔지니어링 기술
AU710880B2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid